MacroGenics, Inc.
NASDAQ:MGNX
1.76 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | MacroGenics, Inc. |
| Symbool | MGNX |
| Munteenheid | USD |
| Prijs | 1.76 |
| Beurswaarde | 111,242,032 |
| Dividendpercentage | 0% |
| 52-weken bereik | 0.99 - 5.1 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Scott Koenig M.D., Ph.D. |
| Website | https://www.macrogenics.com |
An error occurred while fetching data.
Over MacroGenics, Inc.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)








